Malvika Kaul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Malvika Kaul has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Israel Rubinstein
Division of Pulmonary, Critical Care, Sleep and Allergy Medicine, University of Illinois, Chicago, IL, USA
4 shared publications- Ahmed Noor
Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
1 shared publication - Alan Jarman
Division of Academic Internal Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
1 shared publication - Ashima Sahni
Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, USA
1 shared publication - Howard S. Gordon
Jesse Brown Veterans Affairs Medical Center and VA Center of Innovation for Complex Chronic Healthcare, Chicago, IL, USA.
1 shared publication Jessica Gardner
Research Services, Jesse Brown VA Medical Center Chicago, Chicago, IL, USA
1 shared publication
Latest Publications
- Open Access
- 10 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1426
Point-of-Care Ultrasound Use in Hemodynamic Assessment
Hemodynamic assessment is critical in emergency and critical care for preventing, diagnosing, and managing shock states that significantly affect patient outcomes. Point-of-care ultrasound (POCUS) has become an invaluable, non-invasive, real-time, and reproducible tool for bedside decision-making. Advancements such as Doppler imaging, advanced critical care ultrasonography, and transesophageal echocardiography (TEE) have expanded its utility, enabling rapid and repeatable evaluations, especially in complex mixed shock presentations. This review explores the role of POCUS in hemodynamic monitoring, emphasizing its ability to assess cardiac output, filling pressures, and vascular congestion, facilitating shock classification and guiding fluid management. We highlight an extensive array of POCUS techniques for evaluating right and left cardiac function and review existing literature on their advantages, limitations, and appropriate clinical applications. Beyond assessing volume status, this review discusses the role of POCUS in predicting fluid responsiveness and supporting more individualized, precise management strategies. Ultimately, while POCUS is a powerful tool for rapid, comprehensive hemodynamic assessment in acute settings, its limitations must be acknowledged and thoughtfully integrated into clinical decision-making.
- 10 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1426
Open AccessPoint-of-Care Ultrasound Use in Hemodynamic Assessment
Hemodynamic assessment is critical in emergency and critical care for preventing, diagnosing, and managing shock states that significantly affect patient outcomes. Point-of-care ultrasound (POCUS) has become an invaluable, non-invasive, real-time, and reproducible tool for bedside decision-making. Advancements such as Doppler imaging, advanced critical care ultrasonography, and transesophageal echocardiography (TEE) have expanded its utility, enabling rapid and repeatable evaluations, especially in complex mixed shock presentations. This review explores the role of POCUS in hemodynamic monitoring, emphasizing its ability to assess cardiac output, filling pressures, and vascular congestion, facilitating shock classification and guiding fluid management. We highlight an extensive array of POCUS techniques for evaluating right and left cardiac function and review existing literature on their advantages, limitations, and appropriate clinical applications. Beyond assessing volume status, this review discusses the role of POCUS in predicting fluid responsiveness and supporting more individualized, precise management strategies. Ultimately, while POCUS is a powerful tool for rapid, comprehensive hemodynamic assessment in acute settings, its limitations must be acknowledged and thoughtfully integrated into clinical decision-making.
- Open Access
- 1 January 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (1)
New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago
Background A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental oxygen (DSO) therapy among survivors of coronavirus disease 2019 (COVID-19) hospitalisations with persistent hypoxaemia upon discharge. The purpose of this single centre study was to begin to address this issue. Methods In this retrospective study we report features of US military veterans residing in metropolitan Chicago with no prior DSO therapy who survived COVID-19 hospitalisation, were discharged on DSO and were followed for 6 months. Results We found that the majority of the 65 elderly patients (median age, 70 years), predominantly obese Black males, who survived COVID-19 hospitalisations at the Jesse Brown VA Medical Center and were discharged on DSO did not undergo a formal 6-min walk test (6MWT) to re-assess ongoing ambulatory supplemental oxygen requirements (46 patients or 71%). Nonetheless, DSO therapy was discontinued in most patients predominantly within 8 weeks of hospital discharge (34 patients, 52%). In addition, a large proportion of patients, obese Black people in particular, who survived COVID-19 hospitalisations and were treated with DSO for at least 8 weeks thereafter developed post-acute sequelae of COVID-19 infection (PASC) (30 patients, 46%). Conclusions Given these findings, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who survived COVID-19 hospitalisations and were treated with DSO for persistent hypoxaemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and are treated with DSO thereafter have an elevated risk in developing PASC remains to be determined in larger, prospective studies. A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental O2 therapy among survivors of #COVID19 hospitalisation with persistent hypoxaemia upon discharge; hence, proper monitoring and evaluation are recommendedhttps://bit.ly/3HRlfxE
- 1 January 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (1)
Open AccessNew domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago
Background A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental oxygen (DSO) therapy among survivors of coronavirus disease 2019 (COVID-19) hospitalisations with persistent hypoxaemia upon discharge. The purpose of this single centre study was to begin to address this issue. Methods In this retrospective study we report features of US military veterans residing in metropolitan Chicago with no prior DSO therapy who survived COVID-19 hospitalisation, were discharged on DSO and were followed for 6 months. Results We found that the majority of the 65 elderly patients (median age, 70 years), predominantly obese Black males, who survived COVID-19 hospitalisations at the Jesse Brown VA Medical Center and were discharged on DSO did not undergo a formal 6-min walk test (6MWT) to re-assess ongoing ambulatory supplemental oxygen requirements (46 patients or 71%). Nonetheless, DSO therapy was discontinued in most patients predominantly within 8 weeks of hospital discharge (34 patients, 52%). In addition, a large proportion of patients, obese Black people in particular, who survived COVID-19 hospitalisations and were treated with DSO for at least 8 weeks thereafter developed post-acute sequelae of COVID-19 infection (PASC) (30 patients, 46%). Conclusions Given these findings, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who survived COVID-19 hospitalisations and were treated with DSO for persistent hypoxaemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and are treated with DSO thereafter have an elevated risk in developing PASC remains to be determined in larger, prospective studies. A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental O2 therapy among survivors of #COVID19 hospitalisation with persistent hypoxaemia upon discharge; hence, proper monitoring and evaluation are recommendedhttps://bit.ly/3HRlfxE
- 1 November 2021
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 80, 100855
Paradoxical bronchospasm in U.S. military veterans with COPD or asthma at a tertiary VA medical center in Chicago, Illinois
- 1 November 2021
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 80, 100855
Paradoxical bronchospasm in U.S. military veterans with COPD or asthma at a tertiary VA medical center in Chicago, Illinois
- Open Access
- 11 August 2021
- Published by Wiley in Respirology
- Vol. 26 (10) , 914-916
Proposed novel treatment paradigm of aberrant gait and balance kinematics in patients with severe COPD
- 11 August 2021
- Published by Wiley in Respirology
- Vol. 26 (10) , 914-916
Open AccessProposed novel treatment paradigm of aberrant gait and balance kinematics in patients with severe COPD
- 7 July 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 78 (2) , 540-542
Population-Based Magnetic Resonance Imaging: Earlier Detection of Hypertensive Cerebral Small Vessel Disease?
- 7 July 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 78 (2) , 540-542
Population-Based Magnetic Resonance Imaging: Earlier Detection of Hypertensive Cerebral Small Vessel Disease?
- 16 November 2020
- Published by Springer Nature in Current Sleep Medicine Reports
- Vol. 6 (4) , 226-231
Use of Cannabinoids for the Treatment of OSA
- 16 November 2020
- Published by Springer Nature in Current Sleep Medicine Reports
- Vol. 6 (4) , 226-231
Use of Cannabinoids for the Treatment of OSA